Klinischer Nutzen der molekularen Diagnostik pädiatrischer Hirntumore

Die Fortschritte der molekularen Diagnostik haben neue Türen für die Diagnosestellung, Risikostratifizierung und Präzisionsonkologie für Kinder mit Hirntumoren aufgestoßen. Dieses Wissen konsequent und systematisch in einen klinischen Nutzen zu übertragen wird Aufgabe der kommenden Jahre sein.

• Literatur

• 1 Capper D, Stichel D, Sahm F. et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018; 136: 181-210. doi:10.1007/s00401-018-1879-y Epub 2018 Jul 2
• 2 Capper D, Jones DTW, Sill M. et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018; 555: 469-474. doi:10.1038/nature26000 Epub 2018 Mar 14
• 3 Johann PD, Erkek S, Zapatka M. et al. A typical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer cell 2016; 29: 379-393
• 4 Northcott PA, Buchhalter I, Morrissy AS. et al. The whole-genome landscape of medulloblastoma subtypes. Nature 2017; 547: 311-317. doi:10.1038/nature22973
• 5 Pajtler KW, Witt H, Sill M. et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015; 27: 728-743. doi:10.1016/j.ccell.2015.04.002
• 6 Selt F, Deiss A, Korshunov A. et al. Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain pathology 2016; 26: 506-516
• 7 Sturm D, Witt H, Hovestadt V. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22: 425-437. doi:10.1016/j.ccr.2012.08.024
• 8 Sturm D, Orr BA, Toprak UH. et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 2016; 164: 1060-1072
• 9 Sturm D, Jones DTW, Sahm F. et al. Tb-11 molecular Neuropathology 2.0 – Increasing Diagnostic Accuracy in Pediatric Neurooncology. Neuro-oncology 2016; 18: iii170
• 10 Worst BC, van Tilburg CM, Balasubramanian GP. et al. Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. Eur J Cancer 2016; 65: 91-101